Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFRBi-armed T cells in recurrent glioblastoma
NCT02521090Phase 2Withdrawn
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Aug 2015
- Primary completion
- Mar 2016
- Modality
- Bispecific Antibodies, Adoptive Cell Transfer
01
Overview
A Phase 2 trial of EGFR BATs in glioblastoma (GBM), Gliosarcoma (GS), sponsored by Barbara Ann Karmanos Cancer Institute. Planned start Aug 2015; status: withdrawn.
02
Drugs
EGFR BATs
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02521090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521090.